In Q1 2026, OraSure Technologies maintained strong liquidity while navigating ongoing net losses and regulatory complexities. The company’s business model encompasses proprietary diagnostic devices, integrated laboratory services including genomics, and comprehensive sample management solutions underpinned by FDA and international approvals. Its competitive moat is shaped by regulatory barriers, technological differentiation, and distributor networks, although regulatory delays and leadership transitions pose material risks. Looking ahead, product approvals and sales expansion will be critical milestones.